多瑞醫藥(301075.SZ):擬300萬元收購嘉諾康剩餘20%股權
格隆匯1月21日丨多瑞醫藥(301075.SZ)公佈,為進一步優化公司股權投資結構、提高研發平台運營效率,公司擬以自有資金收購武漢藥眾醫藥科技有限公司(簡稱“藥眾醫藥”)所持有的公司控股子公司武漢嘉諾康醫藥技術有限公司(簡稱“嘉諾康”)20.00%股權。交易雙方於近日簽署了《股權轉讓協議》。
嘉諾康主要負責高技術壁壘原料藥和製劑的研發,目前已形成6項已授權發明專利,7項在受理髮明專利;在研項目包括鹽酸胺碘酮、鹽酸多巴胺原料等。交易對方藥眾醫藥系嘉諾康管理及研發團隊成員持股平台。經雙方協商,嘉諾康整體作價1500萬元,該次收購20.00%股權對應的交易總價為300萬元。交易完成後,嘉諾康將成為公司的全資子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.